Oramed Extends $37.2M Scilex Debt Payment, Faces Stock-for-Cash Risk

summarizeSummary

Oramed Pharmaceuticals extended a $37.2 million debt payment deadline for Scilex, with a risk of receiving Scilex stock and a $1.5 million penalty if Scilex defaults on the new September 30, 2026 deadline.

check_boxKey Events · Financing and Capital Events · ORMP

• Debt Extension Granted

  Oramed extended the payment deadline for approximately $37.2 million in outstanding debt from Scilex Holding Company to September 30, 2026. This follows a prior extension to June 15, 2026.

• Immediate Payment Received

  Oramed received $0.5 million on June 25, 2026, with an additional $5 million due by July 31, 2026. The remaining balance is due by September 30, 2026.

• Significant Default Risk

  If Scilex fails to pay by September 30, 2026, Oramed will retroactively lose $1.5 million of payments received (reclassified as an extension fee) and may be forced to accept Scilex common stock for the remaining balance, introducing liquidity and valuation risk.

• Bylaws Amended

  The board approved amendments to the company's bylaws, primarily revising procedures for stockholder action by written consent and director nominations. These are routine corporate governance updates.

auto_awesomeAnalysis · ORMP · Life Sciences

Oramed Pharmaceuticals has granted Scilex Holding Company another extension on approximately $37.2 million in outstanding debt obligations, pushing the final payment deadline to September 30, 2026. This is a significant amount, representing nearly 19% of Oramed's market capitalization. The agreement includes a critical clause: if Scilex defaults, Oramed will forfeit $1.5 million of any payments received (which will be reclassified as an extension fee) and may be forced to accept Scilex common stock instead of cash for the remaining balance. This introduces substantial uncertainty and potential liquidity risk for Oramed regarding a material asset.